EP2939672B1 - Promoter der igf-1-produktion - Google Patents

Promoter der igf-1-produktion Download PDF

Info

Publication number
EP2939672B1
EP2939672B1 EP13866826.4A EP13866826A EP2939672B1 EP 2939672 B1 EP2939672 B1 EP 2939672B1 EP 13866826 A EP13866826 A EP 13866826A EP 2939672 B1 EP2939672 B1 EP 2939672B1
Authority
EP
European Patent Office
Prior art keywords
mass
agent
polymethoxyflavonoid
igf
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13866826.4A
Other languages
English (en)
French (fr)
Other versions
EP2939672A4 (de
EP2939672A1 (de
Inventor
Kazutaka OSHIO
Hirohiko Nakamura
Yasuyuki Sakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Publication of EP2939672A1 publication Critical patent/EP2939672A1/de
Publication of EP2939672A4 publication Critical patent/EP2939672A4/de
Application granted granted Critical
Publication of EP2939672B1 publication Critical patent/EP2939672B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for use in the treatment or amelioration of a disease selected from growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia.
  • the invention further relates to the use of an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for improvement in sport performance, growth promotion, promotion of physical strengthening by body building, promotion of metabolism, or strengthening of muscles, with the proviso that uses for the treatment of the human or animal body by therapy are excluded.
  • IGF-1 insulin-like growth factor 1
  • IGF-1 binds to a target organ, or a receptor of each cell of a tissue
  • signal transfer starts within the cell.
  • mTOR mammalian rapamycin target protein
  • the signal transfer system via mTOR works as a sensor for the amino acid balance in the cellular environment of mammals, and participates in the protein synthesis through control of activities of two of the important regulatory factors involved in the translation of proteins, the S6 kinase 1 (S6K1, Non-patent document 1) and the initiation factor 4E-binding protein (4E-BP1, Non-patent document 2) (Patent document 1, Non-patent documents 3 and 4). It is also known that S6K1 and 4E-BP1 activated by being phosphorylated (Non-patent document 5) .
  • IGF-1 concentration and activated states of S6K1 and 4E-BP1 are frequently used as indexes of protein synthesis.
  • Patent document 2 whey protein hydrolysate
  • Patent document 3 fish ovary membrane
  • Patent document 4 11 ⁇ -hydroxy-4-androstene-3,17-dione
  • Patent document 5 sterol glycoside derived from germinated brown rice
  • extract of Citrus depressa or a polymethoxyflavonoid such as nobiletin and tangeretin has a protein synthesis-promoting action.
  • Patent document 6 gentiopicrin
  • Patent document 7 swertiamarin
  • Patent document 8 molecular species including Fc region of immunoglobulin G
  • Patent document 9 sterol glycoside derived from germinated brown rice
  • Patent document 10 ⁇ -viniferin
  • Patent document 11 Paeonia albiflora extract
  • Patent document 17 Although there has been reported that nobiletin and tangeretin have a neurite outgrowth action (Patent document 17), it is known that synthesis of new protein is not required for the neurite outgrowth (Non-patent document 6). Further, although possibility of treatment of peripheral nerve functional disorders such as amyotrophic lateral sclerosis with them is also mentioned in Patent document 17, the object of this treatment is limited to improvement of a pathological condition caused by neurite outgrowth, and the patent document suggests neither suppression of muscular atrophy nor synthesis of myoproteins.
  • Such polymethoxyflavonoids as mentioned above are scarcely contained in fruit juice, but are mostly contained in pericarps. Therefore, only by squeezing fruits, these polymethoxyflavonoids are obtained only at a low content.
  • Polymethoxyflavonoids constitute one class of flavonoid, have a special structure in which a plurality of phenolic hydroxyl groups are methylated, and are mainly contained in Citrus species. It has also been reported that polymethoxyflavonoids such as nobiletin or tangeretin are metabolized in the liver after ingestion. For example, methoxy groups of nobiletin are converted into hydroxyl groups by metabolism in the liver of rat, and nobiletin derivatives having 4'-OH, 7-OH, 6-OH, 3',4'-diOH, 6,7-diOH or the like are generated as metabolites.
  • Patent document 19 relates to a muscle atrophy inhibitor containing an extract of Citrus depressa as an active ingredient.
  • Patent document 20 describes a specific method for producing a solubilized nobiletin composition.
  • Patent document 21 relates to a method for extending neurites, comprising administering a composition to a subject, the composition comprising a specific polyalkoxyflavonoid and a pharmaceutically acceptable carrier or a food material.
  • An object of the present invention is to provide an IGF-1 production-promoting agent that can be taken safely, and a food or drink comprising it.
  • the inventors of the present invention conducted various researches in order to achieve the aforementioned object. As a result, they found that an extract of Citrus depressa, or a polymethoxyflavonoid as an ingredient thereof had a superior IGF-1 production-promoting action, and accomplished the present invention.
  • the present invention thus provides an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for use in the treatment or amelioration of a disease selected from the group consisting of growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia.
  • the polymethoxyflavonoid is nobiletin and/or tangeretin.
  • the present invention also provides an IGF-1 production-promoting agent comprising an extract of Citrus depressa comprising 0.3 mass % or more of a polymethoxyflavonoid in terms of solid matter as an active ingredient for use in the treatment or amelioration of a disease selected from the group consisting of growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia.
  • the IGF-1 production-promoting agent further comprises a clathrating agent that makes the polymethoxyflavonoid water-soluble.
  • the clathrating agent is cyclodextrin, and content thereof is 0.1 to 95 mass % based on the total mass of the solid matter of the extract of Citrus depressa and cyclodextrin.
  • the IGF-1 production-promoting agent comprises an extract of Citrus depressa comprising 0.2 mass % or more of nobiletin, and/or 0.1 mass % or more of tangeretin in terms of solid matter as an active ingredient.
  • the present invention also provides an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for use in the treatment or amelioration of a disease selected from the group consisting of growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia, wherein the agent is in the form of a food or drink which comprises the aforementioned IGF-1 production-promoting agent in an amount of 0.3 mass % or more as content of the polymethoxyflavonoid in terms of solid matter.
  • the present invention further provides an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for use in the treatment or amelioration of a disease selected from the group consisting of growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia, wherein the agent is in the form of a food or drink which comprises the IGF-1 production-promoting agent, and wherein the food or drink comprises nobiletin in an amount of 0.2 mass % or more as content of nobiletin in terms of solid matter.
  • the present invention also provides an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for use in the treatment or amelioration of a disease selected from the group consisting of growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia, wherein the agent is in the form of a food or drink which comprises the IGF-1 production-promoting agent, and wherein the food or drink comprises tangeretin in an amount of 0.1 mass % or more as content of tangeretin in terms of solid matter.
  • the present invention further provides an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for use in the treatment or amelioration of a disease selected from the group consisting of growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia, wherein the agent is in the form of a food or drink which comprises the IGF-1 production-promoting agent, and wherein the food or drink comprises nobiletin and tangeretin in such an amount that nobiletin content is 0.2 mass % or more in terms of solid matter, and tangeretin content is 0.1 mass % or more in terms of solid matter.
  • the present invention also provides the use of an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for improvement in sport performance, growth promotion, promotion of physical strengthening by body building, promotion of metabolism, or strengthening of muscles, with the proviso that uses for the treatment of the human or animal body by therapy are excluded.
  • the IGF-1 production-promoting agent of the present invention comprises a polymethoxyflavonoid as an active ingredient.
  • the IGF-1 production-promoting agent comprises an extract of Citrus depressa, especially an extract of Citrus depressa comprising 0.3 mass % or more of a polymethoxyflavonoid in terms of solid matter, as an active ingredient.
  • Polymethoxyflavonoids comprised in Citrus depressa or an extract thereof mainly have a structure represented by the following formula, and specific examples include nobiletin, tangeretin, 5-demetylated nobiletin, 8-demethoxylated nobiletin (sinensetin), 6-demethoxylated tangeretin, 6-demethoxylated nobiletin, citromitin, 5,6,7,8,4-pentamethoxyflavanone, and so forth.
  • nobiletin and tangeretin are preferred.
  • R, R 1 , R 2 , R 3 , and R 4 are OMe, OMe, H, Me, and OMe, respectively, in nobiletin, or OMe, H, H, Me, and OMe, respectively, in tangeretin (Me represents methyl group, OMe represents methoxy group, and H represents hydrogen).
  • the polymethoxyflavonoid may consist of a single kind of polymethoxyflavonoid or a mixture of arbitrary two or more kinds of polymethoxyflavonoids.
  • R, R 1 , R 2 , and R 4 independently represent hydrogen atom or methoxy group, and R 3 represents hydrogen atom or methyl group.
  • the polymethoxyflavonoid may be extracted from a fruit, leaf, root, stem etc. of a Citrus species or another plant comprising that substance, or may be produced by chemical synthesis.
  • the extract of Citrus depressa can be produced by, for example, extraction of fruit and/or leaf of Citrus depressa with water and/or an organic solvent.
  • the organic solvent may comprise water.
  • Citrus depressa (Shiikuwasha) is a kind of Citrus species belonging to the family Rutaceae.
  • the fruit and/or leaf may be the whole fruit and/or leaf, or may be a part thereof.
  • the fruit may be pulp or pericarp.
  • the fruit and/or leaf may be used as they are, or may be used after crushing, for example, as a finely crushed product of the fruit and/or leaf having a size of nanometer order.
  • the fruit and/or leaf may be a juice extraction residue of a fruit and/or leaf, or a part thereof.
  • these fruit and/or leaf, a part thereof, crushed product thereof, and juice extraction residue thereof may be referred to as "Citrus depressa fruit and/or leaf etc.”
  • organic solvent examples include alcohols such as methanol, ethanol, propanol, isopropanol, and butanol, esters such as ethyl acetate, acetone, hexane, chloroform, diethyl ether, acetonitrile, these organic solvents comprising water, combination of any of these organic solvents and organic solvents comprising water, and so forth, but among these, ethanol is preferred.
  • water content in the organic solvent is not particularly limited, it is preferably 0 to 90 mass %, and more preferably 0 to 40 mass %.
  • ratio (weight ratio) of the Citrus depressa fruit and/or leaf etc.:organic solvent is preferably 1:0.5 to 1:100, and more preferably 1:1 to 1:20.
  • the method of the extraction is not particularly limited, examples include, for example, a method of adding an organic solvent to Citrus depressa fruit and/or leaf etc., performing extraction preferably for 5 minutes to 3 hours with stirring, and then collecting the liquid layer by a solid/liquid separation means such as filtration or centrifugal separation.
  • a clathrating agent for making the polymethoxyflavonoid water-soluble it is preferable to add a clathrating agent for making the polymethoxyflavonoid water-soluble. If such a clathrating agent is used, effects of improving water solubility, digestion and absorption, and flavor of the polymethoxyflavonoid can be expected.
  • the clathrating agent it is preferable to use a compound for clathrate such as cyclodextrin.
  • amount of the clathrating agent is preferably 0.1 to 95 mass %, and more preferably 1 to 90 mass %, based on the total mass of the solid matter of the extract of Citrus depressa and cyclodextrin.
  • the extract of Citrus depressa of the present invention can also be produced by supercritical extraction. Specifically, it can be produced by, for example, subjecting frozen and crushed Citrus depressa fruit or leaf, or Citrus depressa fruit or leaf powdered by lyophilization or hot air-drying to supercritical extraction performed under the following conditions (a) to (d).
  • the extraction fluid it is possible to use supercritical propane, supercritical ethylene, supercritical 1,1,1,2-tetrafluoroethane, or the like, in order to improve extraction efficiency of the Citrus depressa fruit and/or leaf etc.
  • carbon dioxide carbon dioxide gas
  • the extraction temperature may be appropriately chosen to be in the temperature range of 31.1 to 120°C, but in order to improve the extraction efficiency and increase the content of the polymethoxyflavonoid, especially nobiletin and/or tangeretin, it is preferably in the range of 40 to 100°C, and more preferably in the range of 60 to 80°C.
  • the pressure is preferably in the range of 7.38 to 60 MPa, and more preferably in the range of 20 to 40 MPa.
  • ethanol, water, or the like may be used as an entrainer, in order to improve the extraction efficiency.
  • the extraction time may be appropriately chosen according to the temperature or pressure, it is, for example, preferably in the range of 10 to 50 minutes, and more preferably 20 to 30 minutes.
  • the extraction operation can be performed by using a commercially available apparatus.
  • the extract of Citrus depressa of the present invention can also be produced by subcritical extraction. Specifically, it can be produced by, for example, subjecting frozen and crushed Citrus depressa fruit or leaf, or Citrus depressa fruit or leaf powdered by lyophilization or hot air-drying to subcritical extraction performed under the following conditions (a) to (d).
  • the extraction time of 0 minute means that immediately after the temperature is raised to the objective extraction temperature from the start of the extraction, the temperature is lowered by cooling to the level at the start of the extraction.
  • Examples of the extraction fluid used for the subcritical extraction include, for example, water and carbon dioxide. However, in order to increase safety as food or drink, it is preferable to use water.
  • the extraction temperature may be appropriately chosen to be in the temperature range of 140 to 374°C, but in order to improve the extraction efficiency and increase the content of the polymethoxyflavonoid, especially nobiletin and/or tangeretin, it is preferably in the range of 140 to 180°C.
  • the pressure is preferably in the range of 3 to 10 MPa in the case of using water as the extraction fluid.
  • the extraction time may be appropriately chosen according to the temperature or pressure, it is preferably in the range of 0 to 10 minutes, and more preferably 0 to 5 minutes.
  • the extraction operation can be performed by using a commercially available apparatus.
  • Yields of nobiletin and tangeretin in an extract obtained as described above by the extraction method using water, an organic solvent, or an organic solvent comprising water, supercritical extraction, or subcritical extraction are usually about 0.001 to 3 mass %, and about 0.0001 to 2 mass %, respectively, based on the weight of Citrus depressa fruit and/or leaf etc.
  • the extract of Citrus depressa obtained as described above comprises 0.1 mass % or more, preferably 0.3 mass % or more, more preferably 0.6 mass % or more, still more preferably 1 mass % or more, further preferably 3 mass % or more, and particularly preferably 10 mass % or more, of the polymethoxyflavonoid in terms of solid matter.
  • such an extract of Citrus depressa comprises 0.07 mass % or more, preferably 0.2 mass % or more, more preferably 0.4 mass % or more, still more preferably 0.7 mass % or more, further preferably 2 mass % or more, and particularly preferably 6 mass % or more, of nobiletin in terms of solid matter, and/or 0.04 mass % or more, preferably 0.1 mass % or more, more preferably 0.2 mass % or more, still more preferably 0.4 mass % or more, further preferably 1 mass % or more, and particularly preferably 3 mass % or more, of tangeretin in terms of solid matter.
  • in terms of solid matter has the same meaning as "as amount of solid matter (solid content)".
  • expression that the agent, food or the like comprises X% or more of the extract of Citrus depressa, polymethoxyflavonoid, nobiletin, or tangeretin
  • in terms of solid matter means that the ratio of the amount of the solid matter of the extract of Citrus depressa, polymethoxyflavonoid, nobiletin, or tangeretin to the amount of the solid matter of the agent, food or the like is X%.
  • the extract may be used as it is, or may be used after concentration, and the solvent may be partially or completely removed.
  • concentration or removal of the solvent can be carried out by such methods as various chromatography techniques, distillation, solidification by drying, and recrystallization. It is preferable to remove, in particular, organic solvents desirably not to be comprised in a drug or food or drink, such as methanol, propanol, butanol, ethyl acetate, acetone, hexane, chloroform, and diethyl ether.
  • the extract may be fractionated.
  • the content of the polymethoxyflavonoid such as nobiletin and/or tangeretin can be measured by HPLC or the like.
  • Such an extract of Citrus depressa or polymethoxyflavonoid as described above can be used as it is as an active ingredient of the IGF-1 production-promoting agent (henceforth also referred to as "agent of the present invention"), food, drink, or feed.
  • the extract of Citrus depressa or polymethoxyflavonoid may be in the form of a solution, or it may also be lyophilized or spray-dried in a conventional manner, then stored and used as powder.
  • the agent of the present invention can be used as a drug or an active ingredient thereof as one embodiment.
  • an extract of Citrus depressa as it is, or the polymethoxyflavonoid, or nobiletin and/or tangeretin, or a combination of these with a pharmaceutically acceptable carrier can be orally administered to a mammal including human.
  • Preparation form of the agent of the present invention is not particularly limited, and examples include tablets (including sugar-coated tablets, enteric coated tablets, and buccal tablets), powders, capsules (including enteric capsules and soft capsules), granules (including coated granules), pills, troches, enclosed liposome agents, solutions, pharmaceutically acceptable sustained release preparations of these, and so forth.
  • tablets including sugar-coated tablets, enteric coated tablets, and buccal tablets
  • powders including enteric capsules and soft capsules
  • granules including coated granules
  • pills including coated granules
  • troches enclosed liposome agents
  • pharmaceutically acceptable sustained release preparations of these and so forth.
  • additives commonly used in usual oral drugs as pharmaceutical ingredients such as carrier, excipient, binder, disintegrating agent, lubricant, stabilizer, flavoring agent, diluent, surfactant and solvent, can be used.
  • the extract of Citrus depressa or the polymethoxyflavonoid may be used together with an agent or pharmaceutical composition having an IGF-1 production-promoting action or a protein synthesis-promoting action, which is already known or will be found in future, or an agent or pharmaceutical composition having a muscle atrophy inhibition action, which is already known or will be found in future.
  • the pharmaceutical composition used together may be comprised in the agent of the present invention as one of active ingredients, or may not be comprised in the agent of the present invention, but combined as a separate drug with the agent of the present invention to form a commercial product.
  • Examples of the carrier and excipient used for the aforementioned preparation include lactose, glucose, sucrose, mannitol, potato starch, corn starch, calcium carbonate, calcium phosphate, calcium sulfate, crystalline cellulose, glycyrrhizae radix pulverata, gentianae radix pulverata, and so forth, and examples of the binder include, for example, starch, gelatin, syrup, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, hydroxypropylcellulose, ethylcellulose, methylcellulose, carboxymethylcellulose, and so forth.
  • disintegrating agent examples include starch, agar, gelatin powder, sodium carboxymethylcellulose, calcium carboxymethylcellulose, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, sodium arginate, and so forth.
  • Examples of the lubricant include magnesium stearate, hydrogenated vegetable oil, Macrogol, and so forth, and examples of the colorant include Red No. 2, Yellow No. 4, Blue No. 1, which are allowed to be added to drugs, and so forth.
  • Tablets and granules can be coated with sucrose, hydroxypropylcellulose, purified shellac, gelatin, sorbitol, glycerol, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, methyl methacrylate, methacrylic acid polymer, and so forth, as required.
  • One aspect of the present invention is a polymethoxyflavonoid or an extract of Citrus depressa comprising a polymethoxyflavonoid for use as a drug for promoting IGF-1 production for the treatment or amelioration of a disease selected from growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia.
  • the extract of Citrus depressa is an extract of Citrus depressa comprising 0.3 mass % or more of the polymethoxyflavonoid.
  • Amount of the polymethoxyflavonoid or extract of Citrus depressa comprising a polymethoxyflavonoid comprised in the agent of the present invention is not particularly limited, and can be appropriately chosen.
  • the amount is preferably 0.01 mass % or more, more preferably 0.1 mass % or more, still more preferably 1 mass % or more, and particularly preferably 10 mass % or more, in terms of the amount of the solid matter comprised in the extract of Citrus depressa.
  • the amount of the extract of Citrus depressa comprised in the agent of the present invention is preferably 0.1 mass % or more, more preferably 0.3 mass % or more, still more preferably 0.6 mass % or more, further preferably 1 mass % or more, still further preferably 3 mass % or more, and particularly preferably 10 mass % or more, as content of the polymethoxyflavonoid in terms of solid matter.
  • the maximum content of the extract of Citrus depressa is not particularly limited, it may be, for example, 95 mass % or less, 90 mass % or less, or 50 mass % or less, in terms of the amount of the solid matter in the extract of Citrus depressa, or it may be, for example, 95 mass % or less, 80 mass % or less, 60 mass % or less, or 40 mass % or less, in terms of the amount of the polymethoxyflavonoid.
  • amount of the polymethoxyflavonoid comprised in the agent is preferably 0.001 mass % or more, more preferably 0.01 mass % or more, still more preferably 0.1 mass % or more, further preferably 0.3 mass % or more, still further preferably 0.6 mass % or more, still more further preferably 1 mass % or more, still more further preferably 3 mass % or more, and particularly preferably 10 mass % or more, in terms of solid matter.
  • the maximum content of the polymethoxyflavonoid is not particularly limited, it may be, for example, 95 mass % or less, 80 mass % or less, 60 mass % or less, 40 mass % or less, or 30 mass % or less.
  • the amount of nobiletin comprised in the agent is preferably 0.0007 mass % or more, more preferably 0.07 mass % or more, still more preferably 0.2 mass % or more, further preferably 0.4 mass % or more, still further preferably 2.0 mass % or more, and particularly preferably 5 mass % or more, in terms of solid matter.
  • the maximum content of nobiletin is not particularly limited, it may be, for example, 95 mass % or less, 70 mass % or less, 50 mass % or less, 30 mass % or less, or 10 mass % or less.
  • the amount of tangeretin comprised in the agent is preferably 0.0004 mass % or more, more preferably 0.04 mass % or more, still more preferably 0.1 mass % or more, further preferably 0.2 mass % or more, still further preferably 1 mass % or more, and particularly preferably 2 mass % or more, in terms of solid matter.
  • the maximum content of tangeretin is not particularly limited, it may be, for example, 95 mass % or less, 70 mass % or less, 50 mass % or less, 30 mass % or less, or 10 mass % or less.
  • the contents thereof in the agent may be appropriately chosen to be within the aforementioned ranges.
  • polymethoxyflavonoids such as nobiletin, tangeretin, and other polymethoxyflavonoids
  • the contents thereof in the agent may be appropriately chosen to be within the aforementioned ranges.
  • nobiletin and tangeretin are used as the polymethoxyflavonoid, although it is sufficient that amount of at least one of them is within any of the aforementioned ranges, it is preferred that amounts of the both compounds are within any of the aforementioned ranges.
  • the agent of the present invention has an IGF-1 production-promoting action.
  • IGF-1 is involved in a wide variety of diseases and actions including central nerve diseases (dementia such as Alzheimer's disease, etc.), cardiovascular diseases (myocardial infarction, cerebral infarction, hypertension, etc.), metabolic disorders (obesity, diabetes, hypercholesterolemia, etc.), digestive system and visceral disorders (ulcer, decreased liver function, etc.), locomotorium diseases (rheumatoid arthritis, arthritis, etc.), dermatologic disorders (skin aging, alopecia, etc.), immunity activation actions (NK cell activation, etc.), and so forth (Japanese Patent Laid-open (Kokai) No. 2011-157345 ).
  • the present invention relates to the IGF-1 production-promoting agent for use in the amelioration of growth hormone deficiency in adults, growth hormone deficiency dwarfism, or alopecia.
  • the agent can also be used for the amelioration of central nerve diseases (dementia such as Alzheimer's disease, etc.) ( Cell Mol. Neurobiol., 2010 Apr, 30(3):347-60 ; Brain Res., 2009 Dec 15, 1303:179-94 ), cardiovascular diseases (myocardial infarction, cerebral infarction, hypertension, etc.) ( Clin. Endocrinol. (Oxf), 2005, 63:470-476 ; Circulation, 2004, 110:2260-2265 ), metabolic disorders (obesity, diabetes, hypercholesterolemia, etc.) ( Brain Res., 2009 Dec 15, 1303:179-94 ), digestive system and visceral disorders (ulcer, decreased liver function, etc.) ( J.
  • central nerve diseases such as Alzheimer's disease, etc.
  • cardiovascular diseases myocardial infarction, cerebral infarction, hypertension, etc.
  • Clin. Endocrinol. (Oxf) 2005, 63:470-476 ; Circulation, 2004, 110:2260-2265
  • the agent of the present invention exhibits a protein synthesis-promoting action via the IGF-1 production-promoting action.
  • the IGF-1 production-promoting agent of the present invention it is used for promotion of protein synthesis. Therefore, in this specification, the "IGF-1 production-promoting action” and “IGF-1 production-promoting agent” can be read as “protein synthesis-promoting action” and “protein synthesis-promoting agent”, respectively.
  • the present invention relates to the use of an IGF-1 production-promoting agent comprising a polymethoxyflavonoid as an active ingredient for improvement in sport performance, growth promotion, promotion of physical strengthening by body building, promotion of metabolism, or strengthening of muscles, with the proviso that uses for the treatment of the human or animal body by therapy are excluded.
  • the use as a muscular atrophy inhibitor is excluded from use thereof.
  • the muscular atrophy mentioned above refers to a state that muscle mass decreases due to decrease in number of muscle fibers and decrease in volume of muscle fibers.
  • Time for administration of the agent of the present invention is not particularly limited, and can be appropriately chosen according to a state of an object of the administration.
  • Dose of the agent of the present invention is appropriately chosen depending on age, sex, state of the object of administration, other conditions, and so forth.
  • the dose is preferably chosen to be in the range of 0.01 to 500 (mg/kg/day), and more preferably 1 to 250 (mg/kg/day), as a standard in terms of the amount (mg) per body weight 1kg per day of the solid matter comprised in the extract of Citrus depressa.
  • the agent can be administered at a dose of preferably 0.03 (mg/kg/day) or more, more preferably 0.3 (mg/kg/day) or more, still more preferably 3 (mg/kg/day) or more, and particularly preferably 30 (mg/kg/day) or more, as a standard in terms of the amount (mg) per body weight 1kg per day of the polymethoxyflavonoid comprised in the solid matter of the extract of Citrus depressa.
  • the maximum dose is preferably 150 (mg/kg/day) or less, more preferably 120 (mg/kg/day) or less, still more preferably 90 (mg/kg/day) or less, and particularly preferably 60 (mg/kg/day) or less.
  • the dose of the agent of the present invention in terms of the amount (mg) per body weight 1kg per day of the polymethoxyflavonoid is preferably (0.03 mg/kg/day) or more, more preferably 0.3 (mg/kg/day) or more, still more preferably 3 (mg/kg/day) or more, and particularly preferably 30 (mg/kg/day) or more, as a standard.
  • the maximum dose in this case is preferably 150 (mg/kg/day) or less, more preferably 120 (mg/kg/day) or less, still more preferably 90 (mg/kg/day) or less, and particularly preferably 60 (mg/kg/day) or less.
  • the dose in terms of the amount (mg) per body weight 1kg per day of nobiletin is preferably 0.02 (mg/kg/day) or more, more preferably 0.2 (mg/kg/day) or more, still more preferably 2 (mg/kg/day) or more, and particularly preferably 20 (mg/kg/day) or more, as a standard.
  • the maximum dose in this case is preferably 90 (mg/kg/day) or less, more preferably 72 (mg/kg/day) or less, still more preferably 54 (mg/kg/day) or less, and particularly preferably 36 (mg/kg/day) or less.
  • the dose in terms of the amount (mg) per body weight 1kg per day of tangeretin is preferably 0.01 (mg/kg/day) or more, more preferably 0.1 (mg/kg/day) or more, still more preferably 1 (mg/kg/day) or more, and particularly preferably 10 (mg/kg/day) or more, as a standard.
  • the maximum dose in this case is preferably 60 (mg/kg/day) or less, more preferably 48 (mg/kg/day) or less, still more preferably 36 (mg/kg/day) or less, and particularly preferably 24 (mg/kg/day) or less.
  • the effect can be expected even with a dose of the agent of about 1/10 to 1/100 of the aforementioned ranges.
  • the daily dose of the agent can be administered one time a day, or two or more times a day as divided portions.
  • the agent of the present invention or the extract of Citrus depressa or polymethoxyflavonoid as the active ingredient of the agent may be added to diets (drink or food).
  • the polymethoxyflavonoid, the extract of Citrus depressa comprising a polymethoxyflavonoid, or the agent of the present invention to a drink or food as an active ingredient to produce a drink or food having an IGF-1 production-promoting action as one embodiment of the IGF-1 production-promoting agent.
  • Forms and properties of the food and drink are not particularly limited so long as the effect of the polymethoxyflavonoid or the extract of Citrus depressa is not degraded, and they can be orally ingested, and they can be prepared by using usual raw materials used for foods and drinks and usual methods, except that the polymethoxyflavonoid or the extract of Citrus depressa is added.
  • Such foods as mentioned above are not particularly limited, and they may be in the form of liquid, paste, gelled solid, powder, or the like.
  • examples include, for example, tablet confectioneries, and liquid diets, as well as, for example, flour products such as bread, macaroni, spaghetti, noodles, cake mix, fry powder and bread crumbs; ready-to-eat foods such as instant noodles, pot noodles, retort and cooked foods, canned cooking, foods for microwave heating, instant soup and stew, instant miso soup and Japanese clear soup, canned soup, freeze-dried foods, and other ready-to-eat foods; processed agricultural products such as canned agricultural products, canned fruits, jams and marmalades, pickles, cooked beans, dry agricultural products, and cereals (processed grain products); processed marine products such as canned marine products, fish ham and sausages, seafood paste products, marine dainties, and tsukudani (marine products boiled in soy source) ; processed livestock products such as canned livestock products and pastes, and livestock meat ham and sausages; milks and
  • a feed having an IGF-1 production-promoting action can be prepared, as one embodiment of the IGF-1 production-promoting agent.
  • Form of the feed is not particularly limited.
  • the feed can be prepared by blending cereals such as corn, wheat, barley, rye and milo; vegetable oil meals such as soybean oil meal, rapeseed oil meal, coconut oil meal and linseed oil meal; brans such as wheat bran, rice bran, and defatted rice bran; manufactured meals such as corn gluten meal and corn jam meal; animal or fish-derived feeds such as fish meal, skim milk powder, whey, yellow grease and tallow; yeasts such as torula yeast and brewer's yeast; mineral material feeds such as tribasic calcium phosphate and calcium carbonate; oils and fats; monomeric amino acids; saccharides, and so forth.
  • Examples of the form of the feed include, for example, pet food, livestock feed, fish breeding feed, and so forth.
  • the amount of the polymethoxyflavonoid or extract of Citrus depressa comprised in the food or drink (including feed) of the present invention is not particularly limited, and may be appropriately chosen. However, for example, when an extract of Citrus depressa comprising a polymethoxyflavonoid is used, the amount thereof is preferably 1 mass % or more in terms of the amount of solid matter comprised in the extract of Citrus depressa.
  • the amount of the extract of Citrus depressa comprised in the food or drink is preferably 0.3 mass % or more, more preferably 0.6 mass % or more, still more preferably 3 mass % or more, and particularly preferably 10 mass % or more, in terms of content of the polymethoxyflavonoid.
  • the maximum content of the extract of Citrus depressa is not particularly limited, it may be, for example, 95 mass % or less, 50 mass % or less, 30 mass % or less, 20 mass % or less, or 10 mass % or less, in terms of the amount of solid matter in the extract of Citrus depressa, or it may be, for example, 95 mass % or less, 70 mass % or less, 60 mass % or less, 50 mass % or less, or 40 mass % or less, in terms of the amount of the polymethoxyflavonoid.
  • the amount of the polymethoxyflavonoid comprised in the food or drink is preferably 0.3 mass % or more, more preferably 0.6 mass % or more, still more preferably 3.0 mass % or more, and particularly preferably 10 mass % or more, in terms of solid matter.
  • the maximum content of the polymethoxyflavonoid is not particularly limited, it may be, for example, 95 mass % or less, 70 mass % or less, 60 mass % or less, 50 mass % or less, or 40 mass % or less.
  • the amount of nobiletin comprised in the food or drink is preferably 0.2 mass % or more, more preferably 0.4 mass % or more, still more preferably 2.0 mass % or more, and particularly preferably 5 mass % or more, in terms of solid matter.
  • the maximum content of nobiletin is not particularly limited, it may be, for example, 95 mass % or less, 70 mass % or less, 50 mass % or less, 30 mass % or less, or 10 mass % or less.
  • the amount of tangeretin comprised in the food or drink is preferably 0.1 mass % or more, more preferably 0.2 mass % or more, still more preferably 1.0 mass % or more, and particularly preferably 2 mass % or more, in terms of solid matter.
  • the maximum content of tangeretin is not particularly limited, it may be, for example, 95 mass % or less, 70 mass % or less, 50 mass % or less, 30 mass % or less, or 10 mass % or less.
  • ingredients as milk protein (casein), whey protein (whey), soy protein, whey peptides, branched-chain amino acids (valine, leucine, isoleucine), HMB, glutamine, arginine, ornithine, citrulline, creatine, carnitine, nucleic acids (DNA, RNA), vitamin B6, vitamin C, vitamin D, vitamin E, zinc, magnesium, various polymethoxyflavonoids, and various polyphenols are ingested together with the food or drink of the present invention, it can be expected that higher IGF-1 production-promoting effect is obtainable.
  • These ingredients may be added to the food or drink of the present invention.
  • the food or drink (including feed) of the present invention desirably comprises 5 mg or more, preferably 18 mg or more, and more preferably 180 mg or more, of the extract of Citrus depressa in terms of solid matter in an amount thereof for single ingestion.
  • the food or drink (including feed) of the present invention desirably comprises 1.8 mg or more, preferably 18 mg or more, and more preferably 180 mg or more, of the polymethoxyflavonoid in terms of solid matter in an amount thereof for single ingestion.
  • the food or drink (including feed) of the present invention desirably comprises 1.2 mg or more, preferably 12 mg or more, and more preferably 120 mg or more, of nobiletin in terms of solid matter in an amount thereof for single ingestion.
  • the food or drink (including feed) of the present invention desirably comprises 0.6 mg or more, preferably 6 mg or more, and more preferably 60 mg or more, of tangeretin in terms of solid matter in an amount thereof for single ingestion.
  • the IGF-1 production-promoting effect of extract of Citrus depressa was evaluated in mice under exercise load conditions.
  • the extract of Citrus depressa used (commercial product, ARKRAY) was one obtained by adding cyclodextrin as a clathrating agent to an extract from squeezed residue of Citrus depressa fruits extracted with water-comprising ethanol, and had the following composition according to the usual specification thereof.
  • Solid matter 92 mass % or more Cyclodextrin 50 mass %
  • Nobiletin content and tangeretin content of the extract of Citrus depressa (comprising cyclodextrin) used for the following experiment were 6.9 mass % and 3.4 mass %, respectively.
  • mice of the Run and Run+SE groups For the mice of the Run and Run+SE groups, a treadmill exercise acclimation period of two weeks (frequency, three days/week; exercise load was gradually increased (gradient, 5 to 20%; speed, 5 to 20 m/minute; time, 30 to 60 minutes/day)) was set, and then the mice were subjected to exercise load for 10 weeks (gradient, 20%; 20 m/minute; 60 minutes/day; 5 days/week) .
  • mice of the Cont and Run groups were fed with standard feed AIN-93M (CLEA Japan), and the mice of the Run+SE group were fed with AIN-93M comprising the extract of Citrus depressa at a ratio of 1 mass % over 12 weeks including the exercise acclimation period (free oral ingestion).
  • mice Twelve weeks after the change of the feed, the mice were dissected, and the livers and serum were collected.
  • the expression of IGF-1 mRNA in the liver and concentration of IGF-1 in the serum were measured by real-time PCR and ELISA, respectively.
  • RNA was extracted from the liver tissue by using RNeasy Kit (QIAGEN), and reverse-transcribed by using Thermal Cycler Veriti (Applied Biosystems) and High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) to obtain cDNA.
  • the IGF-1 mRNA expression was measured by real-time PCR performed by using the cDNA obtained above, the primers for amplifying IGF-1 cDNA (Assay ID Mm004395960_ml, Applied Biosystems), real-time PCR apparatus (7500 Fast Real-Time PCR System, Applied Biosystems), and TaqMan Gene Expression Assay (Applied Biosystems).
  • the measurement was performed according to the protocols attached to the kits and the general conditions set in the apparatuses.
  • the amount of gene expression was quantified and analyzed as relative amount based on that obtained in the Cont group, which was taken as 1. Statistically significant differences were examined by statistical processings based on the Tukey test or Tukey-Kramer test.
  • the serum IGF-1 concentration was measured by using IGF-1 ELISA Kit (RSD) according to the protocol attached to the kit.
  • the IGF-1 mRNA expression in the liver was 1.00 ⁇ 0.27 for the Cont group, but it was 1.23 ⁇ 0.30 for the Run group, and 1.67 ⁇ 0.17 for the Run+SE group. Thus, the amount increased to 135.7% in the Run+SE group compared with the Run group (p ⁇ 0.05, S.D. represents standard deviation). On the basis of this result, it was confirmed that expression of IGF-1 mRNA is promoted in the liver by ingestion of the extract of Citrus depressa comprising polymethoxyflavonoids.
  • the IGF-1 concentration in the serum was 101 ⁇ 56 ng/mL for the Cont group, but it was 97 ⁇ 38 ng/mL for the Run group and 179 ⁇ 40 ng/mL for the Run+SE group.
  • the extract of Citrus depressa used for the following experiment was the same as that used in Example 1.
  • As the polymethoxyflavonoid a mixture of 67 mass % of nobiletin and 33 mass % of tangeretin was used.
  • AIN-93M was fed to the mice of the Cont and Fix groups, AIN-93M comprising 1 mass % of the extract of Citrus depressa was fed to the mice of the Fix+SE group, AIN-93M comprising 0.1 mass % of the polymethoxyflavonoid (mixture of 67 mass % of nobiletin and 33 mass % of tangeretin, nobiletin and tangeretin were produced by Tokyo Chemical Industry) was fed to the mice of the Fix+PMF group, AIN-93M comprising 0.07 mass % of nobiletin (Tokyo Chemical Industry) was fed to the mice of the Fix+NOB group, and AIN-93M comprising 0.04 mass % of tangeretin (Tokyo Chemical Industry) was fed to the mice of the Fix+TAN group, each for 3 days (free oral ingestion).
  • AIN-93M comprising 1 mass % of the extract of Citrus depressa was fed to the mice of the Fix+SE group
  • mice On day 4 after the change of the feed, the mice were dissected, and the serum IGF-1 concentration, expression of follistatin mRNA in the gastrocnemius, expression of IGF-1 mRNA in the gastrocnemius, and phosphorylation ratio ( ⁇ + ⁇ ) of p70S6K1 in the gastrocnemius were evaluated.
  • follistatin binds to the TGF- ⁇ family members (TGF- ⁇ , activin, myostatin, etc.) to control or suppress the activities of them.
  • TGF- ⁇ TGF- ⁇ family members
  • activin activin
  • myostatin etc.
  • cytostatic action for TGF- ⁇ growth hormone secretion suppression action for activin
  • action on differentiation of stem cell into fat cell for myostatin cytostatic action for activin
  • protein synthesis is promoted. Therefore, expression of follistatin mRNA serves as a marker of protein synthesis.
  • phosphorylation ratio of p70S6K1 also serves as a marker of protein synthesis.
  • the serum IGF-1 concentration was measured in the same manner as that used in Example 1.
  • the expression of follistatin mRNA in the gastrocnemius was measured in the same manner as that used in Example 1, except that the hind leg gastrocnemius was extracted from each rat, and Assay ID Mm00514982_ml (Applied Biosystems) was used as the primer.
  • Phosphorylation of p70S6K1 was measured by the chemiluminescence method using ECL Western Blotting Analysis System (GE Healthcare Life Science) for bands obtained in SDS-PAGE, then transferred to a PVDF membrane, and bound with primary antibodies (p70S6 kinase ⁇ (C-18), SantaCruz Biotechnology) and secondary antibodies (ECL Anti-Rabbit IgG) .
  • Table 3 show variation of the serum IGF-1 concentration provided by the administration of the extract of Citrus depressa at the time of recovery from muscular atrophy in mice in which the muscular atrophy was induced by tail suspension.
  • Cont represents the control group
  • Fix represents the standard feed administration at the time of recovery from muscular atrophy after tail suspension group
  • Fix+SE represents the Citrus depressa extract administration at the time of recovery from muscular atrophy after tail suspension group.
  • Table 4 show variation of the expression of follistatin mRNA provided by the administration of the polymethoxyflavonoid at the time of recovery from muscular atrophy in mice in which the muscular atrophy was induced by tail suspension.
  • Cont represents the control group
  • Fix represents the standard feed administration at the time of recovery from muscular atrophy after tail suspension group
  • Fix+PMF represents the polymethoxyflavonoid administration at the time of recovery from muscular atrophy after tail suspension group.
  • Table 5 show variation of the expression of IGF-1 mRNA in the gastrocnemius provided by the administration of nobiletin at the time of recovery from muscular atrophy in mice in which the muscular atrophy was induced by tail suspension.
  • Cont represents the control group
  • Fix represents the standard feed administration at the time of recovery from muscular atrophy after tail suspension group
  • Fix+NOB represents the nobiletin administration at the time of recovery from muscular atrophy after tail suspension group.
  • Table 6 show variation of the phosphorylation ratio of p70S6K1 in the gastrocnemius provided by the administration of tangeretin at the time of recovery from muscular atrophy in mice in which the muscular atrophy was induced by tail suspension.
  • Cont represents the control group
  • Fix represents the standard feed administration at the time of recovery from muscular atrophy after tail suspension group
  • Fix+TAN represents the tangeretin administration at the time of recovery from muscular atrophy after tail suspension group.
  • the serum IGF-1 concentration was 252 ⁇ 78 ng/mL for the Cont group, but it was 294 ⁇ 42 ng/mL for the Fix group and 325 ⁇ 34 ng/mL for the Fix+SE group, and thus it increased to 110.5% in the Fix+SE group compared with the Fix group (Table 3).
  • the IGF-1 concentration was further increased by the ingestion of the extract of Citrus depressa. Since the ingestion was allowed only for 3 days in this experiment, significant difference was not seen between the Fix group and the Fix+SE group. However, it is considered that prolonged ingestion of the extract of Citrus depressa can provide IGF-1 production-promoting action and protein synthesis-promoting action.
  • the measurement result of the expression of follistatin mRNA was 1.00 ⁇ 0.27 for the Cont group, but it was 1.10 ⁇ 0.20 for the Fix group and 1.30 ⁇ 0.21 for the Fix+PMF group, and thus the expression of follistatin mRNA increased to 118% in the Fix+PMF group compared with the Fix group (Table 4).
  • the expression of follistatin mRNA was further increased by the ingestion of the polymethoxyflavonoid.
  • the measurement result of the expression of IGF-1 mRNA in the gastrocnemius was 1.00 ⁇ 0.13 for the Cont group, but the expression of IGF-1 mRNA was 1.64 ⁇ 0.15 for the Fix group and 1.75 ⁇ 0.40 for the Fix+NOB group (Table 5), and thus the expression of IGF-1 mRNA increased to 107% in the Fix+NOB group compared with the Fix group.
  • the expression of IGF-1 mRNA was further increased by the ingestion of nobiletin. Since the ingestion was allowed only for 3 days in this experiment, significant difference was not seen between the Fix group and the Fix+NOB group. However, it is considered that prolonged ingestion of nobiletin can provide IGF-1 production-promoting action and protein synthesis-promoting action.
  • the measurement result of the phosphorylation ratio of p70S6K1 in the gastrocnemius was 26.4 ⁇ 4.8 for the Cont group, but it was 42.8 ⁇ 10.2 for the Fix group and 47.8 ⁇ 11.8 for the Fix+TAN group (Table 6), and thus the phosphorylation ratio of p70S6K1 increased to 112% in the Fix+TAN group compared with the Fix group.
  • the phosphorylation ratio of p70S6K1 was further increased by the ingestion of tangeretin. Since the ingestion was allowed only for 3 days in this experiment, significant difference was not seen. However, it is considered that prolonged ingestion of tangeretin can provide protein synthesis-promoting action.
  • the protein synthesis promotion effect of ingestion of the extract of Citrus depressa was evaluated in mice in which muscular atrophy was induced by plaster fixation over two weeks .
  • AIN-93M (CLEA Japan) was given to the rats of the Cont and Fix groups, and AIN-93M comprising 1 mass % of the extract of Citrus depressa was given to the rats of the Fix+SE group for 14 days (free oral ingestion).
  • the phosphorylation ratio of p70S6K1 in the gastrocnemius was 26.3 ⁇ 1.9% for the Cont group, but it was 23.3 ⁇ 0.8% for the Fix group and 29.0 ⁇ 2.5% for the Fix+SE group, and thus it increased to 124.4% in the Fix+SE group compared with the Fix group (p ⁇ 0.05).
  • the extract of Citrus depressa has a protein synthesis-promoting action also on the basis of the phosphorylation ratio of p70S6K1.
  • a mixture having the following composition was tableted in a conventional manner to produce tablet confectionaries having a weight of 250 mg per tablet.
  • Content of the extract of Citrus depressa in 1 g of the obtained tablet confectionaries was 60 mg. Since the polymethoxyflavonoid content in the extract of Citrus depressa used as the raw material was 10% or higher, content of the polymethoxyflavonoid in 1 g of the tablet confectionaries was about 6 mg. There were obtained results suggesting that long-term ingestion of 16 tablets per day of this food provides protein synthesis-promoting action based on IGF-1 production-promoting action.
  • Powder candy Showa Sangyo 86.0 mass % Extract of Citrus depressa (Arkray) 6.0 mass % Citric acid (San-Ei Gen F.F.I.) 4.0 mass % Flavor (San-Ei Gen F.F.I.) 2.0 mass % Emulsifier (Kao) 2.0 mass %
  • Chewable tablets having the following composition and a weight of 250 mg per tablet were produced in a conventional manner.
  • Content of the extract of Citrus depressa in 1 g of the obtained chewable tablets was 200 mg. Since the polymethoxyflavonoid content in the extract of Citrus depressa used as the raw material was 10% or higher, content of the polymethoxyflavonoid in 1 g of the chewable tablets was about 20 mg. There were obtained results suggesting that long-term ingestion of 4 tablets per day of this food provides protein synthesis-promoting action based on IGF-1 production-promoting action.
  • Example 8 Enteral nutrient (concentrate liquid diet)
  • Table 8 (/1000 ml) Mineral mixture Na 900 mg K 1500 mg Ca 750 mg Mg 380 mg Fe 11 mg Vitamin mixture ⁇ -Carotene 1800 ⁇ g Vitamin D 5 ⁇ g ⁇ -Tocopherol 12 mg Vitamin B1 1.6 mg Vitamin B2 1.8 mg Vitamin B6 3 mg Vitamin B12 3 ⁇ g Vitamin C 100 mg
  • Baked confectionery having the following composition was produced in a conventional manner. Content of polymethoxyflavonoids in the obtained confectionery for one person (50 g) was 55 mg. It was observed that ingestion of this food resulted in providing protein synthesis-promoting effect. There were obtained results suggesting that long-term ingestion of this food in the amount for one person per day provides protein synthesis-promoting action based on IGF-1 production-promoting action.
  • an IGF-1 production-promoting agent is provided, as further defined in the claims.
  • the present invention relates to the IGF-1 production-promoting agent for use as a drug in the treatment or amelioration of a disease selected from the group consisting of growth hormone deficiency in adults, growth hormone deficiency dwarfism, and alopecia.
  • the IGF-1 production-promoting agent of the present invention uses the ingredients comprised in Citrus depressa as the active ingredient, it is highly safe, and can be used in the form of food, drink, and so forth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (18)

  1. Ein Mittel zur Förderung der IGF-1-Produktion, umfassend ein Polymethoxyflavonoid als einen Wirkstoff, zur Verwendung bei der Behandlung oder Linderung einer Erkrankung, ausgewählt aus der Gruppe bestehend aus Wachstumshormonmangel bei Erwachsenen, durch Hormonmangel bedingten Kleinwuchs und Alopezie.
  2. Das Mittel zur Verwendung nach Anspruch 1, wobei es sich bei dem Polymethoxyflavonoid um Nobiletin und/oder Tangeretin handelt.
  3. Das Mittel zur Verwendung nach Anspruch 1 oder 2, wobei das Mittel einen Extrakt von Citrus depressa, umfassend 0,3 Massen-% oder mehr eines Polymethoxyflavonoids, bezogen auf Feststoffe, als einen Wirkstoff umfasst.
  4. Das Mittel zur Verwendung nach Anspruch 3, wobei das Mittel ferner ein Mittel zur Bildung von Clathraten umfasst, welches das Polymethoxyflavonoid wasserlöslich macht.
  5. Das Mittel zur Verwendung nach Anspruch 4, wobei das Mittel zur Bildung von Clathraten Cyclodextrin ist und dessen Gehalt 0,1 bis 95 Massen-%, bezogen auf die Gesamtmasse an Feststoffen des Extraktes von Citrus depressa und Cyclodextrin, beträgt.
  6. Das Mittel zur Verwendung nach einem der Ansprüche 3 bis 5, wobei das Mittel einen Extrakt von Citrus depressa, umfassend 0,2 Massen-% oder mehr an Nobiletin, und/oder 0,1 Massen-% oder mehr an Tangeretin, bezogen auf Feststoffe, als einen Wirkstoff umfasst.
  7. Das Mittel zur Verwendung nach einem der Ansprüche 1 bis 6, wobei das Mittel in Form eines Nahrungsmittels oder Getränks vorliegt, welches das Mittel zur Förderung der IGF-1-Produktion in einer Menge von 0,3 Massen-% oder mehr als Gehalt des Polymethoxyflavonoids, bezogen auf Feststoffe, umfasst.
  8. Das Mittel zur Verwendung nach Anspruch 2 oder 6, wobei das Mittel in Form eines Nahrungsmittels oder Getränks vorliegt und die Menge an Nobiletin, welches in dem Nahrungsmittel oder Getränk enthalten ist, 0,2 Massen-% oder mehr, bezogen auf Feststoffe, beträgt, und die Menge an Tangeretin, welches in dem Nahrungsmittel oder Getränk enthalten ist, 0,1 Massen-% oder mehr, bezogen auf Feststoffe, beträgt.
  9. Das Mittel zur Verwendung nach einem der Ansprüche 1 bis 6, wobei das Mittel in Form eines Arzneistoffs vorliegt, welcher das Mittel zur Förderung der IGF-1-Produktion in einer Menge von 0,3 Massen-% oder mehr, als Gehalt des Polymethoxyflavonoids, bezogen auf Feststoffe, umfasst.
  10. Das Mittel zur Verwendung nach Anspruch 2 oder 6, wobei das Mittel in Form eines Arzneistoffs vorliegt und die Menge an Nobiletin, welches in dem Arzneistoff enthalten ist, 0,2 Massen-% oder mehr, bezogen auf Feststoffe, beträgt, und die Menge an Tangeretin, welches in dem Arzneistoff enthalten ist, 0,1 Massen-% oder mehr, bezogen auf Feststoffe, beträgt.
  11. Verwendung eines Mittels zur Förderung der IGF-1-Produktion, umfassend ein Polymethoxyflavonoid als einen Wirkstoff, zur Verbesserung der sportlichen Leistung, Wachstumsförderung, Förderung der körperlichen Stärkung durch Body Building, Förderung des Stoffwechsels oder Stärkung von Muskeln, mit der Maßgabe, dass Verwendungen zur therapeutischen Behandlung des menschlichen oder tierischen Körpers ausgeschlossen sind.
  12. Die Verwendung nach Anspruch 11, wobei es sich bei dem Polymethoxyflavonoid um Nobiletin und/oder Tangeretin handelt.
  13. Die Verwendung nach Anspruch 11 oder 12, wobei das Mittel einen Extrakt von Citrus depressa, umfassend 0,3 Massen-% oder mehr eines Polymethoxyflavonoids, bezogen auf Feststoffe, als einen Wirkstoff umfasst.
  14. Die Verwendung nach Anspruch 13, wobei das Mittel ferner ein Mittel zur Bildung von Clathraten umfasst, welches das Polymethoxyflavonoid wasserlöslich macht.
  15. Die Verwendung nach Anspruch 14, wobei das Mittel zur Bildung von Clathraten Cyclodextrin ist und dessen Gehalt 0,1 bis 95 Massen-%, bezogen auf die Gesamtmasse an Feststoffen des Extraktes von Citrus depressa und Cyclodextrin, beträgt.
  16. Die Verwendung nach einem der Ansprüche 13 bis 15, wobei das Mittel einen Extrakt von Citrus depressa, umfassend 0,2 Massen-% oder mehr an Nobiletin, und/oder 0,1 Massen-% oder mehr an Tangeretin, bezogen auf Feststoffe, als einen Wirkstoff umfasst.
  17. Die Verwendung nach einem der Ansprüche 11 bis 16, wobei das Mittel in Form eines Nahrungsmittels oder Getränks vorliegt, welches das Mittel zur Förderung der IGF-1-Produktion in einer Menge von 0,3 Massen-% oder mehr als Gehalt des Polymethoxyflavonoids, bezogen auf Feststoffe, umfasst.
  18. Die Verwendung nach Anspruch 12 oder 16, wobei das Mittel in Form eines Nahrungsmittels oder Getränks vorliegt und die Menge an Nobiletin, welches in dem Nahrungsmittel oder Getränk enthalten ist, 0,2 Massen-% oder mehr, bezogen auf Feststoffe, beträgt, und die Menge an Tangeretin, welches in dem Nahrungsmittel oder Getränk enthalten ist, 0,1 Massen-% oder mehr, bezogen auf Feststoffe, beträgt.
EP13866826.4A 2012-12-26 2013-06-28 Promoter der igf-1-produktion Active EP2939672B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012283414 2012-12-26
PCT/JP2013/067866 WO2014103410A1 (ja) 2012-12-26 2013-06-28 Ｉｇｆ－１産生促進剤

Publications (3)

Publication Number Publication Date
EP2939672A1 EP2939672A1 (de) 2015-11-04
EP2939672A4 EP2939672A4 (de) 2016-08-17
EP2939672B1 true EP2939672B1 (de) 2019-10-30

Family

ID=51020517

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13866826.4A Active EP2939672B1 (de) 2012-12-26 2013-06-28 Promoter der igf-1-produktion

Country Status (7)

Country Link
US (1) US9801404B2 (de)
EP (1) EP2939672B1 (de)
JP (1) JP6131275B2 (de)
AU (1) AU2013367872B2 (de)
ES (1) ES2765238T3 (de)
TW (1) TW201424743A (de)
WO (1) WO2014103410A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6986345B2 (ja) * 2016-11-18 2021-12-22 ロート製薬株式会社 経口組成物及びその製造方法
CN107281166A (zh) * 2017-06-15 2017-10-24 南宁自健科技有限公司 一种药用植物缓释肠溶胶囊及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3010210B1 (ja) * 1998-09-02 2000-02-21 農林水産省果樹試験場長 マトリックスメタロプロテアーゼ産生阻害剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672870A (ja) * 1992-08-26 1994-03-15 Kanebo Ltd 抗潰瘍剤
JP2000169374A (ja) 1998-12-03 2000-06-20 Ltt Kenkyusho:Kk Ｉｇｆ増強剤
JP2001240539A (ja) * 2000-03-02 2001-09-04 Machida & Machida Shokai:Kk 血圧上昇または血糖上昇を抑制するための薬剤または機能性食品
JP4633897B2 (ja) * 2000-08-17 2011-02-16 長瀬産業株式会社 神経突起伸長剤
JP2004083417A (ja) 2002-08-22 2004-03-18 National Agriculture & Bio-Oriented Research Organization 血管新生抑制剤
JP4585201B2 (ja) * 2004-01-23 2010-11-24 丸善製薬株式会社 アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤
JP2005213178A (ja) * 2004-01-29 2005-08-11 Maruzen Pharmaceut Co Ltd ＴＮＦ−α産生抑制剤、エストロゲン様作用剤及び皮膚外用剤
CN101052391A (zh) 2004-11-08 2007-10-10 爱科来株式会社 过氧化物酶体增殖物激活受体（ppar）活化剂以及使用了该活化剂的药品、补充剂、功能性食品和食品添加剂
JP2006328031A (ja) 2005-05-30 2006-12-07 Asahi Breweries Ltd 筋繊維タイプ移行抑制剤
CA2620013A1 (en) * 2005-08-23 2007-03-01 Wellgen, Inc. Methods for managing adipocyte fat accumulation
JP4800049B2 (ja) 2006-01-31 2011-10-26 一丸ファルコス株式会社 ｍＴＯＲを活性化する製剤及びｍＴＯＲを活性化する方法
EP1987826B1 (de) 2006-02-22 2015-05-27 Kands R&D Corporation Medikament und funktionelles nahrungsmittel zur bekämpfung oder linderung von juckreiz und entzündung
JP2007332118A (ja) 2006-06-19 2007-12-27 Minamide Shoji Kk 神経保護剤
JP2007332119A (ja) 2006-06-19 2007-12-27 Minamide Shoji Kk 抗炎症剤
JP3946238B1 (ja) 2006-07-03 2007-07-18 株式会社日本バリアフリー Ｉｇｆ−１値上昇剤
JP2008074723A (ja) * 2006-09-19 2008-04-03 Karii Life:Kk 可溶化ノビレチン組成物の製造方法
WO2009035055A1 (ja) 2007-09-14 2009-03-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute インスリン様成長因子-１（ｉｇｆ－１）産生促進剤
JP5312063B2 (ja) 2008-01-25 2013-10-09 丸善製薬株式会社 ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、ＩＧＦ−１産生促進剤、ＨＧＦ産生促進剤、ＢＭＰ−２産生促進剤、ＦＧＦ−１８産生促進剤、及び２型テストステロン５α−リダクターゼ産生抑制剤
JP2009263262A (ja) 2008-04-23 2009-11-12 Maruzen Pharmaceut Co Ltd Ｉｇｆ−１産生促進剤及びｈｇｆ産生促進剤
JP2010150177A (ja) 2008-12-25 2010-07-08 Maruzen Pharmaceut Co Ltd Ｆｇｆ−７産生促進剤、ｉｇｆ−１産生促進剤及びｈｇｆ産生促進剤
JP5596317B2 (ja) 2009-08-18 2014-09-24 静岡県公立大学法人 心疾患予防治療剤
JP5778912B2 (ja) 2010-01-05 2015-09-16 株式会社ファンケル Ｉｇｆ−１分泌促進剤
JP5695326B2 (ja) 2010-02-12 2015-04-01 雪印メグミルク株式会社 タンパク質合成促進剤
JP2011241162A (ja) 2010-05-17 2011-12-01 Maruzen Pharmaceut Co Ltd ＦＧＦ−７産生促進剤、ＶＥＧＦ産生促進剤、ＩＧＦ−１産生促進剤、ＨＧＦ産生促進剤、テストステロン５α−リダクターゼ阻害剤及び育毛剤
JP2012121856A (ja) 2010-12-09 2012-06-28 Maruzen Pharmaceut Co Ltd Ｖｅｇｆ産生促進剤、ｉｇｆ−１産生促進剤、ｈｇｆ産生促進剤、及びｂｍｐ−２産生促進剤
JP5742050B2 (ja) * 2011-03-01 2015-07-01 国立研究開発法人農業・食品産業技術総合研究機構 Ｎｋ細胞活性化剤、及びｎｋ細胞活性化方法
JP5846350B2 (ja) * 2011-04-28 2016-01-20 国立大学法人東京農工大学 骨疾患予防又は治療用組成物
CN104023735A (zh) * 2011-12-26 2014-09-03 森永乳业株式会社 肌肉萎缩抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3010210B1 (ja) * 1998-09-02 2000-02-21 農林水産省果樹試験場長 マトリックスメタロプロテアーゼ産生阻害剤

Also Published As

Publication number Publication date
EP2939672A4 (de) 2016-08-17
AU2013367872B2 (en) 2016-05-12
EP2939672A1 (de) 2015-11-04
US20150328182A1 (en) 2015-11-19
WO2014103410A1 (ja) 2014-07-03
TW201424743A (zh) 2014-07-01
JP6131275B2 (ja) 2017-05-17
ES2765238T3 (es) 2020-06-08
AU2013367872A1 (en) 2015-07-09
JPWO2014103410A1 (ja) 2017-01-12
US9801404B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
EP2799083B1 (de) Muskelatrophie-inhibitor
US20080008773A1 (en) Food beverage or feed for the promotion of osteogenesis comprising umbelliferae, liliaceae or compositae plant species
JP6802256B2 (ja) Ｇｌｐ−１分泌促進用組成物及びその製造方法
KR20110005294A (ko) 글루타티온 생산 촉진제, 글루타티온의 결핍에 기인하는 질환의 예방·치료제, 음식품 및 사료
KR20130029415A (ko) 대사 증후군의 예방, 개선 또는 치료용 조성물
JPWO2004112817A1 (ja) セリ科植物由来抽出物およびその製造方法
JP5175442B2 (ja) ヤーコン由来の抗ガン剤
EP2939672B1 (de) Promoter der igf-1-produktion
JP7229513B2 (ja) 脳の機能改善剤および脳の機能改善用飲食品
JP2017193497A (ja) 筋肉増強剤
JP2009269832A (ja) カルシトニン遺伝子関連ペプチド及びインスリン様成長因子−１の産生促進組成物
TW201628613A (zh) 含有多酚之機能性口服組成物
JP2016027042A (ja) Ｇｌｐ−１産生促進剤、ｄｐｐｉｖ阻害剤及びグルコース吸収阻害剤
JP7156639B2 (ja) レスベラトロール誘導体の新規用途
JP5950395B2 (ja) 卵白アルブミン分解物を含有する脂質代謝改善剤
JP2018123077A (ja) Ａｄｌ改善剤
JP2021169430A (ja) 筋繊維維持用組成物
JP6184054B2 (ja) ａｔｒｏｇｉｎ−１遺伝子の発現抑制剤
JP2003012527A (ja) 過食抑制剤
JP2009167154A (ja) 血糖値上昇抑制剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160715

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 21/06 20060101ALN20160712BHEP

Ipc: A61P 21/00 20060101ALI20160712BHEP

Ipc: A61K 47/40 20060101ALI20160712BHEP

Ipc: A61K 36/00 20060101ALI20160712BHEP

Ipc: A61P 43/00 20060101ALI20160712BHEP

Ipc: A23L 33/105 20160101ALI20160712BHEP

Ipc: A61K 36/75 20060101ALI20160712BHEP

Ipc: A61K 31/352 20060101AFI20160712BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171214

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/352 20060101AFI20160712BHEP

Ipc: A61K 36/00 20060101ALI20160712BHEP

Ipc: A61K 36/75 20060101ALI20160712BHEP

Ipc: A61P 43/00 20060101ALI20160712BHEP

Ipc: A23L 33/105 20160101ALI20160712BHEP

Ipc: A61P 21/06 20060101ALN20160712BHEP

Ipc: A61P 21/00 20060101ALI20160712BHEP

Ipc: A61K 47/40 20060101ALI20160712BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 21/06 20060101ALN20160712BHEP

Ipc: A61P 43/00 20060101ALI20160712BHEP

Ipc: A23L 33/105 20160101ALI20160712BHEP

Ipc: A61P 21/00 20060101ALI20160712BHEP

Ipc: A61K 36/00 20060101ALI20160712BHEP

Ipc: A61K 47/40 20060101ALI20160712BHEP

Ipc: A61K 31/352 20060101AFI20160712BHEP

Ipc: A61K 36/75 20060101ALI20160712BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 21/00 20060101ALI20190410BHEP

Ipc: A23L 33/105 20160101ALI20190410BHEP

Ipc: A61K 36/00 20060101ALI20190410BHEP

Ipc: A61P 21/06 20060101ALN20190410BHEP

Ipc: A61P 43/00 20060101ALI20190410BHEP

Ipc: A61K 31/352 20060101AFI20190410BHEP

Ipc: A61K 36/75 20060101ALI20190410BHEP

Ipc: A61K 47/40 20060101ALI20190410BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190517

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1195413

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013062360

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200302

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200130

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200131

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200130

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200229

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2765238

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200617

Year of fee payment: 8

Ref country code: NL

Payment date: 20200513

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013062360

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1195413

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20200701

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200628

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200628

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200628

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013062360

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210701

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210629